

ONCOLOGY DISCHARGE RECORD FOR SYN010

ONCOLOGICAL DIAGNOSIS

- Primary: BRAF V600E-mutated non-small cell lung adenocarcinoma (diagnosed January 15, 2023)
- Stage: IV with bone metastases (right femur, T5, T9, L2 vertebrae, right scapula)
- Biomarker status: PDL1 TPS <1% (negative), CPS 3%, IC 1%
- Risk factors: None (never-smoker)

COMORBIDITIES & COMPLICATIONS

- Pathological fracture, right femoral neck (surgically stabilized January 10, 2024)
- Iron deficiency anemia
- Iatrogenic hypothyroidism (BRAF/MEK inhibitor-related)
- Drug-induced fever syndrome
- Anxiety disorder
- Osteopenia (pre-existing)

TREATMENT HISTORY SUMMARY

Ms. Chen was diagnosed following evaluation of persistent bone pain in December 2022. Imaging revealed multiple bone lesions and a 2.1cm left upper lobe lung nodule. Biopsy confirmed adenocarcinoma with BRAF V600E mutation.

First-line therapy with Dabrafenib 150mg BID and Trametinib 2mg daily was initiated on February 6, 2023, with excellent response. In December 2023, patient developed progression of right femoral lesion requiring prophylactic surgical stabilization in January 2024. After thorough discussion with the patient, it was decided to continue targeted therapy despite progress.

Current hospitalization was for management of persistent high-grade fever (101-103°F) with associated constitutional symptoms and transaminitis attributed to BRAF/MEK inhibitor therapy.

HOSPITAL COURSE HIGHLIGHTS

- Drug holiday from Dabrafenib/Trametinib resulted in rapid resolution of fever
- LFTs improved with temporary drug discontinuation
- Targeted therapy successfully reintroduced at 50% dose reduction
- Endocrine management of iatrogenic hypothyroidism optimized
- Iron deficiency addressed with IV iron supplementation

KEY LABORATORY MARKERS

Initial:

- Hemoglobin: 9.8 g/dL
- Ferritin: 15 ng/mL
- AST/ALT: 58/72 U/L
- TSH: 8.4 µIU/mL (Free T4: 0.7 ng/dL)
- CRP: 3.8 mg/dL

Discharge:

- Hemoglobin: 10.2 g/dL (post-iron infusion)
- AST/ALT: 42/48 U/L

- TSH: 6.2 μ IU/mL (improving)
- CRP: 1.2 mg/dL

****IMAGING OVERVIEW****

CT Chest/Abdomen/Pelvis (04/08/2024):

- Primary lung lesion reduced to 0.8 cm (from initial 2.1 cm)
- Known bone metastases with sclerotic healing
- No new metastatic sites
- Stable post-surgical changes in right femur

****CURRENT MEDICATIONS****

1. Dabrafenib 75mg PO BID (\downarrow from 150mg)
2. Trametinib 1mg PO daily (\downarrow from 2mg)
3. Levothyroxine 112mcg PO daily (\uparrow from 88mcg)
4. Oxycodone 5mg PO q6h PRN
5. Acetaminophen 650mg PO q6h PRN
6. Ferrous sulfate 325mg PO TID
7. Vitamin D3 2000 IU PO daily
8. Calcium carbonate 600mg PO BID
9. Escitalopram 10mg PO daily
10. Zolpidem 5mg PO qhs PRN

****FOLLOW-UP SCHEDULE****

- Medical Oncology (Dr. Zhang): 04/20/2024
- Endocrinology (Dr. Friedman): 04/27/2024
- Hematology infusions: 04/17 & 04/24/2024
- Orthopedic Oncology (Dr. Barrett): 05/11/2024
- Imaging: CT & bone scan in June 2024

****CLINICAL ASSESSMENT****

Ms. Chen continues to demonstrate good response to BRAF/MEK inhibitor, with successful management of drug-related toxicity through dose modification. Primary tumor and bone metastases remain well controlled. Prognosis remains favorable with current disease status: responding with ongoing clinical benefit.

****SPECIAL INSTRUCTIONS****

- Weekly LFT monitoring for 4 weeks
- Daily temperature monitoring; report fever $>100.4^{\circ}\text{F}$
- Continue iron supplementation as prescribed
- Weight-bearing as tolerated on right leg
- Maintain thyroid function follow-up

****ONCOLOGIST SIGNATURE:****

Katherine Zhang, MD
Board Certified Medical Oncology
April 13, 2024 | 14:30

****BASIC PATIENT DATA****

Full name: Sophia Chen
Date of birth: August 8, 1975
Age: 49 years

Sex: Female

Admission: April 7, 2024

Discharge: April 13, 2024

Primary oncologist: Katherine Zhang, MD